Dr Reddys Laboratories today said it has launched a generic version of pegfilgrastim injection,used in cancer therapy under the brand Peg- grafeel in India.
Peg-grafeel will offer patients in India an important alternative. An affordable pegfilgrastim will define the way patients undergoing treatment with chemotherapy can reduce the duration of neutropenia…, Dr Reddys Vice-Chairman and CEO GV Prasad said in a filing to the Bombay Stock Exchange (BSE).
Neutropenia is a condition in which a patient has lower than normal white blood cell count,a common side effect of chemotherapy.
Pegfilgrastim developed by Amgen Inc was approved for use in 2002,and is sold as Neulasta in the US market and European Union,it added.
Dr Reddys said its Peg-grafeel is priced at Rs 8,865 per vial. According to the company,the product is priced at nearly 25 per cent of the originator brand in India.
We also intend to market Peg-grafeel globally,on our own and through our partners, Prasad said.
Pegfilgrastim is marketed in India by several companies,including F Hoffmann-La Roche.
Shares of Dr Reddys Laboratories today closed at Rs 1,591 on the BSE,down 0.19 per cent from the previous close.